Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

The effect of oral and intravenous antimicrobials on pulmonary exacerbation recovery in cystic fibrosis

Journal of Cystic Fibrosis(2021)10.1016/j.jcf.2021.02.012Source: DataRank Database

The effect of oral and intravenous antimicrobials on pulmonary exacerbation recovery in cystic fibrosis is a research paper published in Journal of Cystic Fibrosis (2021). On theSindex it has a DataRank of 0.670. It has been cited 10 times, with 8 citing works in its 1-hop citation network.

N/A

0.670DataRank · unranked

Scored on demand from live citation data

Deposits data Open Access10 citations · 8 citing works in its network

Free full text

Cite:

Data availability

Repositories this paper deposited data in (declared in PubMed).

ClinicalTrials.govNCT01104402

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (14 grants)Impact (FWCI 1.17)OA: greenTopics (34)IDs (PubMed, OpenAlex)SDGs (3)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 54%Citation Network 46%

Base Score Contribution

0.360

From this paper's citation signal

Citation Network Contribution

0.310

From 6 citing papers with measurable signal

Learn more about DataRank methodology →

Top 5 citers driving the network score

Ranked by each citer's contribution to N(p) — log1p(C_q) divided by its reference count — out of 8 citers.

Evaluation of clinically relevant changes in the lung clearance index in children with cystic fibrosis and healthy controls
Thorax202220 citations29 referencesContributes 0.105
Outpatient parenteral antibiotic therapy (OPAT) for the management of bronchiectasis
Heliyon20233 citations18 referencesContributes 0.077
Lung Function Recovery from Pulmonary Exacerbations Treated with Oral Antibiotics in Primary Ciliary Dyskinesia
Annals of the American Thoracic Society20244 citations24 referencesContributes 0.067
Home Spirometry in Children with Cystic Fibrosis
Bioengineering20239 citations39 referencesContributes 0.059
Pulmonary Function Tests in the Evaluation of Early Lung Disease in Cystic Fibrosis
Journal of Clinical Medicine202317 citations58 referencesContributes 0.050

Authors (6)

Sonya L. Heltshe ORCID,M. Skalland ORCID,Noah Lechtzin ORCID,Dave P. Nichols ORCID,Christopher H. Goss ORCID

Live enrichment

PubMed:33685776 OpenAlex:https://openalex.org/W3134991353

National Institutes of Health

Grant: R01HL103965

National Institutes of Health

Grant: UL1 TR000423

National Institutes of Health

Grant: U01 HL114589

National Institutes of Health

Grant: P30 DK089507

National Institutes of Health

Grant: UM1 HL119073

US Food and Drug Administration

Grant: R01 FD003704

US Food and Drug Administration

Grant: R01 FD006848

National Institutes of Health

Grant: 5P30DK089507-02

Translational Research Center for Expedite Novel Therapies in Cystic Fibrosis

National Institutes of Health

Grant: 5UM1HL119073-02

Proof of Principle Evaluation of IV Gallium Nitrate in Patients with CF

National Institutes of Health

Grant: 4U01HL114589-04

OPTIMIZE - DCC

National Institutes of Health

Grant: 5R01FD006848-02

A Phase 1b, Multi-center Study of IV Gallium Nitrate in Patients with Cystic Fibrosis who are colonized with Nontuberculosis Mycobacterium (The ABATE Study).

National Institutes of Health

Grant: 5R01HL103965-04

Early Intervention in Pulmonary Exacerbation in CF

National Institutes of Health

Grant: 4R01FD003704-04

Phase 2 Study of Intravenous Gallium Nitrate in the Treatment of Cystic Fibrosis

National Institutes of Health

Grant: 3UL1TR000423-07S1

Institute of Translational Health Sciences

FWCI

1.17

Citation Percentile

0.8%

Citation Trend

2022

2023

2024

2025

greenLicense: Elsevier Non-Commercial

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/8418627

publisherhttps://api.elsevier.com/content/article/PII:S1569199321000473?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S1569199321000473?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.jcf.2021.02.012

Fields of Study

Cystic Fibrosis Research AdvancesChronic Obstructive Pulmonary Disease (COPD) ResearchAsthma and respiratory diseases03 medical and health sciences0302 clinical medicine

MeSH Terms

Symptom Flare UpAdministration, OralAdolescentAdultAnti-Bacterial AgentsCystic FibrosisFemaleForced Expiratory VolumeHumansMaleRetrospective StudiesSpirometry

Keywords

MedicineSpirometryCystic fibrosisInternal medicineExacerbationAntimicrobialAsthmaAdultMaleAdolescentAdministration, OralSymptom Flare UpAnti-Bacterial AgentsForced Expiratory VolumeHumansFemaleRetrospective Studies

Sustainable Development Goals

SDG 3: 3. Good healthSDG 16: 16. Peace & justiceSDG 0: Good health and well-being

Related Papers (1)

Standardisation of spirometry

N/A

1.4DataRank · unranked

European Respiratory Journal(2005)

co-cited

10.1183/09031936.05.00034805